| Ημερομηνία | barcode | code | περιεχομενο | τιμή παραγωγός | χονδρική | λιανική |
|---|---|---|---|---|---|---|
| 05/2018 | 2802769201012 | 276920101 | LUCENTIS INJ.SOL 10MG/ML BT x 1 VIAL +1 filter needle+1 injection needle + 1 syringe +1 filter needle+1 injection needle + 1 syringe | 627.63 | 637.04 | 722.53 |
| 05/2018 | 2802769201029 | 276920102 | LUCENTIS INJ.SOL 10MG/ML BTx1PF.SYRx0,165ML | 627.63 | 637.04 | 722.53 |
| 05/2018 | 2802769201043 | 276920104 | LUCENTIS INJ.SOL 10MG/ML BT x 1 VIAL + 1 διηθητική βελόνη | 627.63 | 637.04 | 722.53 |
For the treatment of patients with neovascular (wet) age-related macular degeneration.
Ranibizumab binds to the receptor binding site of active forms of VEGF-A, including the biologically active, cleaved form of this molecule, VEGF<sub>110</sub>. The binding of ranibizumab to VEGF-A prevents the interaction of VEGF-A with its receptors (VEGFR1 and VEGFR2) on the surface of endothelial cells, reducing endothelial cell proliferation, vascular leakage, and new blood vessel formation.
Approximately 3 days